SCHEMBL32664225

SCHEMBL32664225

Cc1oc2cc(O)ccc2c1C(=O)NC12CC(C1)C2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 1/20 0.44
▸ FAAH O00519 1/20 0.43
▸ GAA P10253 4/20 0.41
▸ POLB P06746 1/20 0.41
▸ ALDH1A1 P00352 6/20 0.41
▸ KDM4E B2RXH2 5/20 0.41
▸ HPGD P15428 4/20 0.41
▸ GLA P06280 2/20 0.41
▸ F12 P00748 1/20 0.41
▸ HSD17B3 P37058 2/20 0.40
▸ HSD17B10 Q99714 3/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ SLC22A12 Q96S37 1/20 0.40
▸ CA12 O43570 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ AKR1B1 P15121 1/20 0.40
▸ UGT1A1 P22309 1/20 0.40
▸ MAOB P27338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32664280 0.80 GAA (0.41) GAAPOLBALDH1A1KDM4EHPGD
SCHEMBL5241666 0.78 GAA (0.52) GAAPOLBALDH1A1KDM4EHPGD
SCHEMBL944525 0.78 GAA (0.52) GAAPOLBALDH1A1KDM4EHPGD
SCHEMBL32664123 0.78 GAA (0.43) GAAPOLBALDH1A1KDM4EHPGD
SCHEMBL32664128 0.78 PKM (0.52) GAAPOLBALDH1A1KDM4EHPGD
SCHEMBL32664129 0.76 GAA (0.48) GAAPOLBALDH1A1KDM4EHPGD
SCHEMBL32664144 0.75 PKM (0.42) GAAPOLBALDH1A1KDM4EHPGD
SCHEMBL5240410 0.75 GAA (0.56) GAAPOLBALDH1A1KDM4EHPGD
SCHEMBL32664147 0.74 PKM (0.41) GAAPOLBALDH1A1KDM4EHPGD
SCHEMBL2083566 0.73 ALDH1A1 (0.54) GAAPOLBALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022125-A1 PYRROLOPYRIDAZINE VEGFR INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-01-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022125-A1 PYRROLOPYRIDAZINE VEGFR INHIBITORS FLT1, KDR, FLT4 CNR2 103/4885FAAH 2238/4885GAA 4611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback